Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,434 shares of the biopharmaceutical company’s stock after acquiring an additional 328 shares during the period. Atlantic Union Bankshares Corp’s holdings in Regeneron Pharmaceuticals were worth $1,259,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in REGN. Sunbelt Securities Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Sutton Wealth Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $40,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Royal Bank of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a “neutral” rating in a report on Tuesday, February 6th. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $967.59.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock worth $13,124,641 in the last three months. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $3.81 during trading on Friday, reaching $962.49. The company’s stock had a trading volume of 461,867 shares, compared to its average volume of 442,739. The company has a 50-day moving average price of $958.93 and a two-hundred day moving average price of $880.12. The firm has a market cap of $105.64 billion, a PE ratio of 27.70, a P/E/G ratio of 2.82 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period last year, the firm posted $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.